Concentrations of ofloxacin in ear and nasal tissues.
The results of two kinetic studies examining soft tissue, cartilage and bone after uptake of oral ofloxacin [administered as 200 mg twice daily (study I/nose) or 400 mg once daily (study II/ear)] show that antibiotic concentrations lie within the therapeutic range. Findings demonstrate that 400 mg ofloxacin daily is a compliance-enhancing and effective approach to the treatment of ENT-related infections, in particular those caused by problem organisms such as Pseudomonas aeruginosa.
Tolsdorff
P
P
ENT Department, Kath. Krankenhaus Siebengebirge, Bad Honnef, Federal Republic of Germany.
D000284:Administration, Oral; D000328:Adult; D002781:Cholesteatoma / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D004425:Ear Cartilage / Q000378:metabolism; D004432:Ear, Middle / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000378:metabolism; D009295:Nasal Bone / Q000378:metabolism; D009296:Nasal Cavity / Q000378:metabolism; D009297:Nasal Mucosa / Q000378:metabolism; D015242:Ofloxacin / Q000097:blood / Q000493:pharmacokinetics*; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology
D015242:Ofloxacin